3EZ, 20Ac-ingenol-induced Apoptosis in Chemoresistant Cancers With Cyclin D1 Accumulation

Shohei Miyata1, Tomonori Nakamura2, Susumu Kitanaka3

  • 1Department of Chemistry, College of Humanities and Sciences, Nihon University, Tokyo, Japan s.miya0024@mbr.nifty.com.

Anticancer Research
|October 28, 2020
PubMed
Abstract

Insights

The novel compound 3EZ, 20Ac-ingenol effectively induces apoptosis in cancer cells by enhancing the DNA damage response (DDR). This topoisomerase 1 inhibitor shows promise against chemoresistant cells, including those with cyclin D1 accumulation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cyclin D1 accumulation is linked to chemoresistance in cancer cells treated with DNA damage agents.
  • Human B lymphoma (BALL-1) cells exhibit high nuclear cyclin D1 levels.
  • 3EZ, 20Ac-ingenol is a topoisomerase 1 catalytic inhibitor.

Purpose of the Study:

  • To investigate the mechanism of apoptosis induction by 3EZ, 20Ac-ingenol in cancer cells.
  • To determine the role of DNA damage response (DDR) in 3EZ, 20Ac-ingenol-mediated apoptosis.
  • To assess the efficacy of 3EZ, 20Ac-ingenol in cells with high cyclin D1 levels.

Main Methods:

  • Cell proliferation was assessed using MTT assays.
  • Protein levels were analyzed via immunoblotting.
  • Apoptosis was quantified using DNA fragmentation assays.

Main Results:

  • 3EZ, 20Ac-ingenol significantly inhibited cell proliferation and induced apoptosis in Jeko-1 and Panc-1 cell lines.
  • The compound activated tumor suppressor proteins and caspase 3.
  • Apoptosis was mediated through enhanced DNA damage response (DDR), involving ATR activation and PTEN up-regulation.

Conclusions:

  • 3EZ, 20Ac-ingenol effectively induces apoptosis in cancer cells with cyclin D1 accumulation.
  • The mechanism involves enhancing the DNA damage response (DDR).
  • This effect appears independent of cancer cell type, suggesting broad applicability.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.7K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.3K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
37.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.0K